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dressings, a pressure reducing surface, repositioning, and
debridement.
RESULTS: Our modeling predicted the total expected cost
of standard care treatment for a stage 3 pressure ulcer to
be $20,874. Randomized clinical trials have found that
NNWT (n  72 patients) decreases the surface area of
stage 3-4 pressure ulcers by 2.5 fold (SD 59%) over stan-
dard care (n  59 patients). The eight-week healing rates
for stage 3 ulcers are 71% with NNWT and 54% for stan-
dard care. At these healing rates, our modeling for stage 3
pressure ulcers found that for a 40 month time frame
NNWT saves $6,630 (SE $98) and increases QALYs by
0.10 (SE 0.0005) life years compared to standard care. For
stage 4 pressure ulcers, NNWT saves $15,216(SE $186)
and increases QALYs by 0.14 (SE 0.001).
CONCLUSIONS: NNWT in patients with stage 3 and 4
pressure ulcer is an economically attractive intervention.
Additional well-controlled clinical trials are necessary to
further define the role of NNWT in the care of chronic
wounds.
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Psoriasis is a chronic disease, which affects 4.7 % of the
French population. Even if it is not a question of a vital
prognosis, it is a very invalidating condition in daily life
because of the damage to the body image.
OBJECTIVE: Evaluate the Quality of Life consequences
for patients with psoriasis, in France.
METHOD: Four thousand five hundred anonymous
questionnaires were sent, via a Patient Support Group
acting against Psoriasis (Association Pour la Lutte Contre
le Psoriasis, APLCP). The questionnaires consisted of two
scales: the Psoriasis Disability Index and 10 questions
concerning the treatment and evolution of psoriasis.
RESULTS: Twenty-five days after the mailing, 2014
questionnaires (44%) were received. An analysis of the
first questionnaire was conducted. The respondents were
54% women, average age was 50 years, and for men, 53
years. The average age at diagnosis for men was 30 years,
and for women, 25 years. Women are significantly more
adversely affected than men in their everyday activities.
Men are significantly more adversely affected than women
at work. No difference was observed between men’s and
women’s global scores. Psoriasis seems to incapacitate 16
to 55 year olds in their social relations, leisure activities
and how well they keep their house more than it does
older subjects. Long-standing psoriasis does not seem to
be more of a handicap to people than more recent psoria-
sis. The global score is similar. However, a clear trend is
observed between the age at the moment of diagnosis and
the level of incapacity (p  .0176). The younger the indi-
vidual in which psoriasis is diagnosed, the higher the level
of incapacity. This is particularly marked in terms of the
everyday and leisure scores.
CONCLUSION: These results highlight the value of ap-
propriate and relevant psychological and medical envi-
ronment for children suffering from psoriasis.
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OBJECTIVE: For patients with atopic dermatitis, long-
term treatment is usually unavoidable and various limita-
tions are caused in their daily life. Therefore, the influ-
ence on the patient of new, innovative pharmacotherapy
for atopic dermatitis is thought to be extremely large
from an economic viewpoint. In this study, we attempted
to measure willingness to pay (WTP) for the newly devel-
oped therapeutic agent, “tacrolimus”.
METHODS: 1,000 men and women, 20–59 years old and
living in the Tokyo metropolitan area, were selected by
random sampling for the interview survey. The bidding
game method and the take-it-or-leave-it approaches were
adopted. Eight patterns of health-care costs for one month
(from 625 to 80,000 yen) were allocated to each respon-
dent at random to avoid “starting point bias”. We esti-
mated the demand curve, assuming that the log transfor-
mation of WTP will be distributed as a logistic function.
RESULTS: A total of 431 interviews (43.1% of the can-
didates) were completed. More than half responded as
“yes” to the price of 10,000 yen or less. The demand
curve was estimated to be: P(x)1/(1  exp(5.5239 
0.5906 ln(x))). The median of WTP was 11,537 yen
(95% CI: 8,967–14,845).
CONCLUSION: It can be interpreted that the average
amount people are willing to pay for tacrolimus pharma-
cotherapy is 11,500 yen a month. This information is
considered to be beneficial for clinical decision-making as
well as policy decision-making such as price setting and
reimbursement decisions.
NEUROLOGICAL DISORDERS
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OBJECTIVE: The Family Hardiness Index (FHI) has
been used to glean insight into the functionality of the
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family unit (in terms of family commitment, confidence,
challenge, and control) as a potential factor influencing
outcomes of care for ill children. A potential consequence
of care giving is the loss of time or performance in other
aspects of the caregiver’s life (for instance work or aca-
demic productivity).
METHODS: We measured family hardiness and produc-
tivity using validated instruments that provide index
measures for each; family hardiness index (FHI) and
work productivity and activity index (WPAI) in 60 fami-
lies presenting to a pediatric neurology clinic. The FHI
score was used to stratify families into three groups: low
hardiness (FHI  40); medium hardiness (FHI  41–50),
and high hardiness (FHI  51–60). Participating families
were dichotomized into two groups based on WPAI: fam-
ilies whose caregiver reported a WPAI decrement, and
families whose caregiver reported no WPAI decrement.
Relative odds were calculated using chi-square test of as-
sociation (univariate) to determine the association of FHI
with WPAI. The odds of reporting a WPAI decrement
were calculated for each FHI strata compared with the
highest FHI stratum.
RESULTS: The relative odds, 95% CI (p  value) of re-
porting a WPAI decrement in the low (FHI 
 40) and
medium (FHI 41–50) strata compared to the high (FHI
51–60) stratum were 3.4, 0.3 to 35.0 (p  0.29) and 1.3,
0.3 to 5.4 (p  0.73), respectively.
CONCLUSION: Recognizing factors associated with dis-
ease burden may allow providers of epilepsy care to offer
families additional supportive services that may be associ-
ated with important indirect consequences of disease, such
as productivity. Although not significant, our results sug-
gest that family hardiness might be useful for this purpose,
however further validation studies are needed. The influ-
ence of seizure severity and therapy type on productivity
should also be determined using a multivariate approach.
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OBJECTIVES: This study is the first to compare adverse
reaction reports of rivastigmine and donepezil using real-
world data.
METHODS: This study uses the 2000 FDA Quarterly
Data from the Adverse Event Reporting System (AERS).
Total prescription and sales data for rivastigmine and
donepezil was utilized to determine the number of pa-
tients prescribed each drug. Adverse drug reaction mea-
surements as a proportion of users of each drug were
then obtained. Analyses tested proportional differences.
RESULTS: The most frequent common adverse reactions
were nausea and malaise for rivastigmine, and interac-
tions and convulsions for donepezil. Results show no sta-
tistically significant differences between rivastigmine and
donepezil in total rate of adverse drug reactions and rate
of serious adverse drug reactions. In contrast, the rate of
common adverse events found in donepezil was signifi-
cantly higher compared to its product labeling (p  .05).
The adverse event rate from drug interactions is signifi-
cantly higher for donepezil (p  .05).
CONCLUSIONS: As indicated from the FDA’s AERS,
similar rates of adverse events and serious adverse events
for rivastigmine and donepezil were found. Efficacy and
concomitant medication usage should be considerations
when selecting therapies for Alzheimer’s disease.
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OBJECTIVES: To assess the cost-effectiveness of high fre-
quency stimulation of the subthalamic nucleus (DBS-STN)
in patients with idiopathic Parkinson’s disease (PD).
METHODS: Sixteen PD patients were treated with DBS-
STN. Clinical evaluations were done at baseline and at 1,
3, 6 and 12 months following surgery by means of the
UPDRS. To evaluate the quality of life we included the
Sickness Impact Profile at baseline and at six months af-
ter surgery. Relevant economic data were taken from
medical records and costs were derived from different
German medical economic resources. Costs were deter-
mined from the perspective of the health-care provider.
RESULTS: Following DBS-STN UPDRS, subscores de-
creased as well as the sum score of UPDRS. Quality of
life improved considerably in PD patients treated with
DBS-STN. The physical dimension score (p  .009) as
well as the overall SIP score was different (p  .01) six
months after surgery compared to baseline values. Mean
costs of DM 40,020 per patient were spent during the 12-
month observation period for inpatient and outpatient
care. These expenses included the cost for the electronic
device for bilateral stimulation. Following DBS-STN,
medication was considerably reduced. Mean daily drug
costs at baseline were DM 46.7  21.8 and DM 18.3 
17.7 at 12 months following DBS-STN. Furthermore, we
used cost and UPDRS scores to estimate the incremental
cost-effectiveness of DBS-STN relative to baseline treat-
ment patterns. Treatment with DBS-STN had higher costs
but was more effective than baseline treatment. The in-
cremental CE ratio for DBS-STN was DM 1.800 for one
unit of decrease of the UPDRS.
CONCLUSIONS: DBS-STN is an effective treatment,
which considerably alleviates the severity and signs and
symptoms and improves the quality of life of patients
